Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 47

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 47
---
 shares for the 2021 Plan. If the Equity Plan Increase is not approved, we believe that we would be forced to rely on providing higher levels of
cash compensation or cash-settled awards for a portion of our incentive-based compensation in order to retain our most experienced and skilled employees, which we believe would put us at a significant competitive disadvantage in our industry and
would not be in our stockholders’ best interests, as it would remove incentives aligning the interests of our employees and our senior leaders with those of our stockholders to drive company-wide performance and create long-term stockholder
value, and would reduce the amount of cash that we have available to dedicate to our other business needs. Given that equity awards, and in particular stock options, are a critical part of the compensation at pharmaceutical companies of our stage,
the inability to grant equity awards under the 2021 Plan would put us in significant jeopardy of losing key employees and executive officers, and would make it much more difficult for us to retain employees and executive officers, all of which would
be detrimental to the interests of Aadi and its stockholders.

Risk Factors

In evaluating the proposals described herein, you should carefully read this proxy statement and especially consider the factors discussed in the sections
entitled “Risk Factors Related to the Divestiture, the PIPE Financing, the License Agreement and the ADC Programs” beginning on page 34 and “AADI Risk Factors” beginning on page 229.

Risk Factors Related to the Divestiture, the PIPE Financing, the License Agreement and the ADC Programs(see page 34)

- 31 -

Risks Related to the Pending Divestiture

| • |     | The pendency of the Divestiture could have an adverse effect on our business and results of operations, and the                                                   
 failure to complete the Divestiture in a timely manner or at all could adversely affect our business, financial condition, results of operations and stock price. |

| • |     | The Divestiture is subject to conditions, some or all of which may not be satisfied, or completed on a timely                                                                                                                                     
 basis, if at all. There can be no guarantees that the Divestiture will be completed. Failure to complete, or unexpected delays in completing, the Divestiture or any termination of the Divestiture Agreement could have an adverse effect on our 
 financial condition and results of operations.                                                                                                                                                                                                    |

| • |     | While the Divestiture is pending, we are subject to business uncertainties and contractual restrictions that